Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

Element Science Announces First Patient Save with Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)

Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors

Septerna Strengthens Leadership Team to Advance Novel Small Molecule GPCR Medicines

Flare Therapeutics Appoints Amit Rakhit, M.D. As President And Chief Executive Officer

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis

Rheos Medicines Receives FDA “Study May Proceed” Letter to Initiate Phase 1 Clinical Study Under its Investigational New Drug Application for RHX-317 for Treatment of Autoimmune and Inflammatory Diseases

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

Revolution Medicines Announces Commencement of Public Offering of Common Stock

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering

Fulcrum Therapeutics Announces Departure of Chief Medical Officer

Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Goldfinch Bio Announces Publication in Science Advances on the Validation of Human Derived Organoids as a Predictable and Translatable Preclinical Model in Kidney Disease for the Evaluation of Therapeutic Drug Candidates

Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update

Asher Bio Appoints Independent Director Bob Deresiewicz, M.D., to its Board

Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

Ambys Medicines Announces Formation of Clinical and Scientific Advisory Boards with Leading Liver Disease and Cell and Gene Therapy Experts

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

Asher Bio Appoints Andrea Pirzkall, M.D., as Chief Medical Officer

Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial

Asher Bio Announces Clinical Trial Collaboration with Merck to Evaluate AB248 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors

Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development

Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines

Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs

Ambys Medicines Presents New Data Further Validating its Novel Liver Cell Replacement Therapy Platform at the ASGCT Annual Meeting

Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas

Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations From MGTA-117 Clinical Trial and Other Program Highlights

Rheos Medicines CSO Dania Rabah to Deliver Keynote Address at AAPS National Biotechnology Conference

Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update

Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

MOMA Therapeutics Announces $150 Million Series B Financing

Rheos Medicines Announces Publication of New Data to Support Targeting MALT1 to Treat Autoimmune and Inflammatory Diseases

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809

Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis

insitro Announces Formation of Scientific Advisory Board to Support Platform and Pipeline Advancement